相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Novel strategies of protecting non-cancer cells during chemotherapy: Are they ready for clinical testing?
Zbigniew Darzynkiewicz
Oncotarget (2015)
Pharmacological manipulation of the cell cycle and metabolism to protect normal tissues against conventional anticancer drugs
Ingeborg van Leeuwen et al.
Oncotarget (2015)
Xenotropic murine leukemia virus-related virus (XMRV) in prostate cancer cells likely represents a laboratory artifact
Jiawen Yang et al.
Oncotarget (2015)
Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancer
Helen M. Coley et al.
Oncotarget (2015)
Post-slippage multinucleation renders cytotoxic variation in anti-mitotic drugs that target the microtubules or mitotic spindle
Yanting Zhu et al.
CELL CYCLE (2014)
LZTS1 downregulation confers paclitaxel resistance and is associated with worse prognosis in breast cancer
Francesca Lovat et al.
ONCOTARGET (2014)
HDAC 1/4-mediated silencing of microRNA-200b promotes chemoresistance in human lung adenocarcinoma cells
Dong-Qin Chen et al.
ONCOTARGET (2014)
Targeting CDC25C, PLK1 and CHK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer
Nader Al Nakouzi et al.
ONCOTARGET (2014)
Transposon activation mutagenesis as a screening tool for identifying resistance to cancer therapeutics
Li Chen et al.
BMC CANCER (2013)
Epigenetic regulation of MDR1 gene through post-translational histone modifications in prostate cancer
Rui Henrique et al.
BMC GENOMICS (2013)
Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit?
Man Yu et al.
CANCER AND METASTASIS REVIEWS (2013)
Protect and serve Bcl-2 proteins as guardians and rulers of cancer cell survival
Frederique Braun et al.
CELL CYCLE (2013)
Targeting mitotic exit with hyperthermia or APC/C inhibition to increase paclitaxel efficacy
Serena Giovinazzi et al.
CELL CYCLE (2013)
Identification of a novel role of Septin 10 in paclitaxel-resistance in cancers through a functional genomics screen
Mingli Xu et al.
CANCER SCIENCE (2012)
The response to PAK1 inhibitor IPA3 distinguishes between cancer cells with mutations in BRAF and Ras oncogenes
Ruchi Singhal et al.
ONCOTARGET (2012)
Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection
Alessandra Biffi et al.
BLOOD (2011)
Polo-like Kinase Plk2 Is an Epigenetic Determinant of Chemosensitivity and Clinical Outcomes in Ovarian Cancer
Nelofer Syed et al.
CANCER RESEARCH (2011)
The PKA paradox Is Bim the answer?
Andrew M. Coley et al.
CELL CYCLE (2011)
Long-Distance Effects of Insertional Mutagenesis
Ruchi Singhal et al.
PLOS ONE (2011)
Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture
Pasha Apontes et al.
ONCOTARGET (2011)
Protein kinase A is a target for aging and the aging heart
Linda C. Enns et al.
AGING-US (2010)
A Chemosensitization Screen Identifies TP53RK, a Kinase that Restrains Apoptosis after Mitotic Stress
David Peterson et al.
CANCER RESEARCH (2010)
Class III β-Tubulin Expression Predicts Prostate Tumor Aggressiveness and Patient Response to Docetaxel-Based Chemotherapy
Guillaume Ploussard et al.
CANCER RESEARCH (2010)
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Johann Sebastian de Bono et al.
LANCET (2010)
Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer
C. N. Sternberg et al.
ANNALS OF ONCOLOGY (2009)
USP15 plays an essential role for caspase-3 activation during Paclitaxel-induced apoptosis
Mingli Xu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
Overexpression of Kinesins Mediates Docetaxel Resistance in Breast Cancer Cells
Sarmishtha De et al.
CANCER RESEARCH (2009)
Validation-based insertional mutagenesis identifies lysine demethylase FBXL11 as a negative regulator of NFκB
Tao Lu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Transposon-based mutagenesis identifies short RIP1 as an activator of NFκB
Maupali Dasgupta et al.
CELL CYCLE (2008)
A Natural Human Retrovirus Efficiently Complements Vectors Based on Murine Leukemia Virus
Beihua Dong et al.
PLOS ONE (2008)
Taxane refractory prostate cancer
Paul Mathew et al.
JOURNAL OF UROLOGY (2007)
Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs
Charles Swanton et al.
CANCER CELL (2007)
Chemoresistant KM12C colon cancer cells are addicted to low cyclic AMP levels in a phosphodiesterase 4-regulated compartment via effects on phosphoinositide 3-kinase
David G. McEwan et al.
CANCER RESEARCH (2007)
Synthetic lethal screen identification of chemosensitizer loci in cancer cells
Angelique W. Whitehurst et al.
NATURE (2007)
Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy
Tateki Yoshino et al.
CLINICAL CANCER RESEARCH (2006)
Efficient trafficking of MDR1/P-glycoprotein to apical canalicular plasma membranes in HepG2 cells requires PKA-RIIα anchoring and glucosylceramide
Kacper A. Wojtal et al.
MOLECULAR BIOLOGY OF THE CELL (2006)
A phase I safety and dose escalation trial of docetaxel combined with GEM®231, a second generation antisense oligonucleotide targeting protein kinase A R1α in patients with advanced solid cancers
S Goel et al.
INVESTIGATIONAL NEW DRUGS (2006)
FMDV-2A sequence and protein arrangement contribute to functionality of CYP2B1-reporter fusion protein
J Lengler et al.
ANALYTICAL BIOCHEMISTRY (2005)
Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance
JP MacKeigan et al.
NATURE CELL BIOLOGY (2005)
Mutagenesis by reversible promoter insertion to study the activation of NF-κB
ES Kandel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
DP Petrylak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
The pro-apoptotic protein Bim is a convergence point for cAMP/protein kinase A- and glucocorticoid-promoted apoptosis of lymphoid cells
LZ Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Activation of Akt/protein kinase B overcomes a G2/M cell cycle checkpoint induced by DNA damage
ES Kandel et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
Paclitaxel-induced FasL-independent apoptosis and slow (non-apoptotic) cell death
MV Blagosklonny et al.
CANCER BIOLOGY & THERAPY (2002)
Taxol-induced cell cycle arrest and apoptosis: dose-response relationship in lung cancer cells of different wild-type p53 status and under isogenic condition
GC Das et al.
CANCER LETTERS (2001)
Dominant effector genetics in mammalian cells
X Xu et al.
NATURE GENETICS (2001)
Expression of the multidrug resistance gene in human prostate cancer
G Bhangal et al.
UROLOGIC ONCOLOGY (2000)
分享论文
